| 2023-10-02 |
Lassen Therapeutics Inc. |
Results Lassen Therapeutics Presents Preclinical Data on LASN01, an Anti-IL-11 Receptor Antibody in Development for Treatment of Thyroid Eye Disease at the American Thyroid Association 2023 Annual Meeting lassentherapeutics.com ↗
In preclinical studies, LASN01 led to the suppression of cell proliferation and hyaluronan secretion from primary TED orbital fibroblasts, in addition to demonstrating anti-fibrotic activity. |
| 2023-09-11 |
Lassen Therapeutics Inc. |
Results Lassen Therapeutics Presents New Data on LASN01 for the Treatment of Idiopathic Pulmonary Fibrosis and Thyroid Eye Disease at the European Respiratory Society (ERS) and European Thyroid Association (ETA) Annual Meetings lassentherapeutics.com ↗
We have completed our Phase 1 single ascending and multiple ascending dose cohorts and presented data from our healthy volunteer study at ERS. |
| 2023-05-24 |
Lassen Therapeutics Inc. |
Results Lassen Therapeutics Presents Phase I Data on LASN01, an IL-11 Receptor-Blocking Antibody for Treatment of Pulmonary Fibrosis, at the American Thoracic Society 2023 Annual Meeting lassentherapeutics.com ↗
|
| 2023-05-09 |
Lassen Therapeutics Inc. |
Results Lassen Therapeutics Announces Oral Presentation of Phase I Data of LASN01, an IL-11 Receptor-Blocking Antibody for Treatment of Pulmonary Fibrosis, at the American Thoracic Society 2023 Annual Meeting lassentherapeutics.com ↗
In the Phase I study, LASN01 exhibited dose-linear pharmacokinetics, with an excellent safety profile in healthy volunteers. |
| 2022-06-15 |
Lassen Therapeutics Inc. |
Results Lassen Therapeutics Presents New Preclinical Data on IL-11 Receptor-blocking as a Novel Therapeutic Approach for Skin Fibrosis at Keystone Symposia Conference lassentherapeutics.com ↗
Following TGFβ stimulation, anti-IL11R antibodies reduced collagen expression in primary IPF patient fibroblasts and decreased expression of procollagen I and metallopeptidase 1 (TIMP1) by precision cut lung slices (PCLS) from healthy donors. |
| 2022-05-17 |
Lassen Therapeutics Inc. |
Results Lassen Therapeutics Presents Data Demonstrating Preclinical Anti-fibrotic Effect of LASN01, a Novel IL-11 Receptor-Blocking Antibody, at the American Thoracic Society 2022 Annual Meeting lassentherapeutics.com ↗
The data demonstrate that LASN01 is a potent inhibitor of IL-11 signaling and shows anti-fibrotic effects in multiple preclinical models. |